Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab sequential therapy for acne fulminans
ChiCTR2600132301Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vunakizumab and isotretinoin in acne fulminans (AF), sponsored by Huashan Hospital. Primary endpoints: Relative change rate in inflammatory lesion count (including nodules/cysts) and Global Acne Grading System. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
vunakizumabisotretinoin
03
Conditions
acne fulminans (AF)
Beyond the preview
Go deeper on ChiCTR2600132301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132301.